nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—lung cancer	0.377	0.788	CbGaD
Gliclazide—ALB—lung cancer	0.101	0.212	CbGaD
Gliclazide—ALB—Gefitinib—lung cancer	0.0454	0.19	CbGbCtD
Gliclazide—CYP2C19—Gefitinib—lung cancer	0.0294	0.123	CbGbCtD
Gliclazide—CYP2C19—Teniposide—lung cancer	0.0285	0.119	CbGbCtD
Gliclazide—ALB—Erlotinib—lung cancer	0.0268	0.112	CbGbCtD
Gliclazide—CYP2C9—Gefitinib—lung cancer	0.0245	0.102	CbGbCtD
Gliclazide—ALB—Irinotecan—lung cancer	0.0242	0.101	CbGbCtD
Gliclazide—CYP2C9—Teniposide—lung cancer	0.0237	0.0991	CbGbCtD
Gliclazide—CYP2C9—Paclitaxel—lung cancer	0.0132	0.0553	CbGbCtD
Gliclazide—ALB—Methotrexate—lung cancer	0.0128	0.0536	CbGbCtD
Gliclazide—CYP2C9—Cisplatin—lung cancer	0.0106	0.0445	CbGbCtD
Gliclazide—KCNJ11—mammary gland—lung cancer	0.00125	0.145	CbGeAlD
Gliclazide—ABCC8—mammary gland—lung cancer	0.00115	0.134	CbGeAlD
Gliclazide—VEGFA—bronchus—lung cancer	0.000959	0.111	CbGeAlD
Gliclazide—VEGFA—trachea—lung cancer	0.000861	0.1	CbGeAlD
Gliclazide—ALB—mammary gland—lung cancer	0.000825	0.0959	CbGeAlD
Gliclazide—VEGFA—cardiac atrium—lung cancer	0.000809	0.094	CbGeAlD
Gliclazide—VEGFA—bone marrow—lung cancer	0.000683	0.0794	CbGeAlD
Gliclazide—VEGFA—lung—lung cancer	0.000619	0.0719	CbGeAlD
Gliclazide—Glyburide—ABCC3—lung cancer	0.000566	0.455	CrCbGaD
Gliclazide—CYP2C9—mammary gland—lung cancer	0.000515	0.0599	CbGeAlD
Gliclazide—VEGFA—lymph node—lung cancer	0.000423	0.0492	CbGeAlD
Gliclazide—KCNJ11—lymph node—lung cancer	0.000303	0.0352	CbGeAlD
Gliclazide—Glyburide—ABCG2—lung cancer	0.000275	0.221	CrCbGaD
Gliclazide—ALB—lymph node—lung cancer	0.0002	0.0232	CbGeAlD
Gliclazide—Chlorpropamide—ABCB1—lung cancer	0.000169	0.136	CrCbGaD
Gliclazide—Glyburide—ALB—lung cancer	0.00012	0.0964	CrCbGaD
Gliclazide—Glyburide—ABCB1—lung cancer	0.000114	0.092	CrCbGaD
Gliclazide—Epistaxis—Methotrexate—lung cancer	5.88e-05	0.000379	CcSEcCtD
Gliclazide—Hypersensitivity—Irinotecan—lung cancer	5.88e-05	0.000379	CcSEcCtD
Gliclazide—Convulsion—Docetaxel—lung cancer	5.86e-05	0.000378	CcSEcCtD
Gliclazide—Paraesthesia—Paclitaxel—lung cancer	5.85e-05	0.000377	CcSEcCtD
Gliclazide—Hypertension—Docetaxel—lung cancer	5.84e-05	0.000376	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—lung cancer	5.82e-05	0.000375	CcSEcCtD
Gliclazide—Agranulocytosis—Methotrexate—lung cancer	5.82e-05	0.000375	CcSEcCtD
Gliclazide—Dyspnoea—Paclitaxel—lung cancer	5.8e-05	0.000374	CcSEcCtD
Gliclazide—Somnolence—Paclitaxel—lung cancer	5.79e-05	0.000373	CcSEcCtD
Gliclazide—Myalgia—Docetaxel—lung cancer	5.76e-05	0.000371	CcSEcCtD
Gliclazide—Chest pain—Docetaxel—lung cancer	5.76e-05	0.000371	CcSEcCtD
Gliclazide—Arthralgia—Docetaxel—lung cancer	5.76e-05	0.000371	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—lung cancer	5.75e-05	0.000371	CcSEcCtD
Gliclazide—Nausea—Vinorelbine—lung cancer	5.75e-05	0.00037	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Etoposide—lung cancer	5.73e-05	0.000369	CcSEcCtD
Gliclazide—Dyspepsia—Paclitaxel—lung cancer	5.73e-05	0.000369	CcSEcCtD
Gliclazide—Body temperature increased—Cisplatin—lung cancer	5.73e-05	0.000369	CcSEcCtD
Gliclazide—Asthenia—Irinotecan—lung cancer	5.73e-05	0.000369	CcSEcCtD
Gliclazide—Fatigue—Etoposide—lung cancer	5.72e-05	0.000369	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	5.72e-05	0.000368	CcSEcCtD
Gliclazide—Pain—Etoposide—lung cancer	5.68e-05	0.000366	CcSEcCtD
Gliclazide—Constipation—Etoposide—lung cancer	5.68e-05	0.000366	CcSEcCtD
Gliclazide—Dry mouth—Docetaxel—lung cancer	5.63e-05	0.000363	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—lung cancer	5.63e-05	0.000363	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Paclitaxel—lung cancer	5.62e-05	0.000362	CcSEcCtD
Gliclazide—Fatigue—Paclitaxel—lung cancer	5.61e-05	0.000362	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—lung cancer	5.6e-05	0.000361	CcSEcCtD
Gliclazide—Asthenia—Gemcitabine—lung cancer	5.58e-05	0.00036	CcSEcCtD
Gliclazide—Constipation—Paclitaxel—lung cancer	5.57e-05	0.000359	CcSEcCtD
Gliclazide—Pain—Paclitaxel—lung cancer	5.57e-05	0.000359	CcSEcCtD
Gliclazide—Confusional state—Docetaxel—lung cancer	5.56e-05	0.000359	CcSEcCtD
Gliclazide—Pharyngitis—Methotrexate—lung cancer	5.56e-05	0.000358	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—lung cancer	5.53e-05	0.000356	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—lung cancer	5.51e-05	0.000355	CcSEcCtD
Gliclazide—Pruritus—Gemcitabine—lung cancer	5.5e-05	0.000355	CcSEcCtD
Gliclazide—Infection—Docetaxel—lung cancer	5.48e-05	0.000353	CcSEcCtD
Gliclazide—Feeling abnormal—Etoposide—lung cancer	5.47e-05	0.000353	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—lung cancer	5.46e-05	0.000352	CcSEcCtD
Gliclazide—Diarrhoea—Irinotecan—lung cancer	5.46e-05	0.000352	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—lung cancer	5.43e-05	0.00035	CcSEcCtD
Gliclazide—Gastrointestinal pain—Etoposide—lung cancer	5.43e-05	0.00035	CcSEcCtD
Gliclazide—Nervous system disorder—Docetaxel—lung cancer	5.41e-05	0.000349	CcSEcCtD
Gliclazide—Thrombocytopenia—Docetaxel—lung cancer	5.4e-05	0.000348	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—lung cancer	5.4e-05	0.000348	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—lung cancer	5.39e-05	0.000348	CcSEcCtD
Gliclazide—Tachycardia—Docetaxel—lung cancer	5.39e-05	0.000347	CcSEcCtD
Gliclazide—Feeling abnormal—Paclitaxel—lung cancer	5.36e-05	0.000346	CcSEcCtD
Gliclazide—Skin disorder—Docetaxel—lung cancer	5.36e-05	0.000345	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—lung cancer	5.35e-05	0.000345	CcSEcCtD
Gliclazide—Hypersensitivity—Cisplatin—lung cancer	5.34e-05	0.000344	CcSEcCtD
Gliclazide—Gastrointestinal pain—Paclitaxel—lung cancer	5.32e-05	0.000343	CcSEcCtD
Gliclazide—Diarrhoea—Gemcitabine—lung cancer	5.32e-05	0.000343	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—lung cancer	5.31e-05	0.000342	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—lung cancer	5.29e-05	0.000341	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—lung cancer	5.29e-05	0.000341	CcSEcCtD
Gliclazide—Dizziness—Irinotecan—lung cancer	5.28e-05	0.00034	CcSEcCtD
Gliclazide—Urticaria—Etoposide—lung cancer	5.27e-05	0.00034	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—lung cancer	5.26e-05	0.000339	CcSEcCtD
Gliclazide—Abdominal pain—Etoposide—lung cancer	5.25e-05	0.000338	CcSEcCtD
Gliclazide—Body temperature increased—Etoposide—lung cancer	5.25e-05	0.000338	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—lung cancer	5.25e-05	0.000338	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—lung cancer	5.25e-05	0.000338	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—lung cancer	5.23e-05	0.000337	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—lung cancer	5.22e-05	0.000336	CcSEcCtD
Gliclazide—Asthenia—Cisplatin—lung cancer	5.2e-05	0.000335	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—lung cancer	5.18e-05	0.000334	CcSEcCtD
Gliclazide—Urticaria—Paclitaxel—lung cancer	5.17e-05	0.000333	CcSEcCtD
Gliclazide—Hypotension—Docetaxel—lung cancer	5.16e-05	0.000332	CcSEcCtD
Gliclazide—Abdominal pain—Paclitaxel—lung cancer	5.15e-05	0.000332	CcSEcCtD
Gliclazide—Body temperature increased—Paclitaxel—lung cancer	5.15e-05	0.000332	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—lung cancer	5.11e-05	0.000329	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—lung cancer	5.09e-05	0.000328	CcSEcCtD
Gliclazide—Vomiting—Irinotecan—lung cancer	5.08e-05	0.000327	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—lung cancer	5.07e-05	0.000326	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—lung cancer	5.04e-05	0.000325	CcSEcCtD
Gliclazide—Rash—Irinotecan—lung cancer	5.03e-05	0.000324	CcSEcCtD
Gliclazide—Dermatitis—Irinotecan—lung cancer	5.03e-05	0.000324	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Docetaxel—lung cancer	5.03e-05	0.000324	CcSEcCtD
Gliclazide—Chills—Methotrexate—lung cancer	5.02e-05	0.000324	CcSEcCtD
Gliclazide—Headache—Irinotecan—lung cancer	5e-05	0.000322	CcSEcCtD
Gliclazide—Insomnia—Docetaxel—lung cancer	4.99e-05	0.000322	CcSEcCtD
Gliclazide—Diarrhoea—Cisplatin—lung cancer	4.96e-05	0.00032	CcSEcCtD
Gliclazide—Paraesthesia—Docetaxel—lung cancer	4.95e-05	0.000319	CcSEcCtD
Gliclazide—Vomiting—Gemcitabine—lung cancer	4.94e-05	0.000319	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—lung cancer	4.93e-05	0.000318	CcSEcCtD
Gliclazide—Dyspnoea—Docetaxel—lung cancer	4.92e-05	0.000317	CcSEcCtD
Gliclazide—Somnolence—Docetaxel—lung cancer	4.91e-05	0.000316	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—lung cancer	4.9e-05	0.000316	CcSEcCtD
Gliclazide—Rash—Gemcitabine—lung cancer	4.9e-05	0.000316	CcSEcCtD
Gliclazide—Dermatitis—Gemcitabine—lung cancer	4.9e-05	0.000316	CcSEcCtD
Gliclazide—Hypersensitivity—Etoposide—lung cancer	4.89e-05	0.000315	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—lung cancer	4.87e-05	0.000314	CcSEcCtD
Gliclazide—Erythema—Methotrexate—lung cancer	4.87e-05	0.000314	CcSEcCtD
Gliclazide—Headache—Gemcitabine—lung cancer	4.87e-05	0.000314	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—lung cancer	4.86e-05	0.000313	CcSEcCtD
Gliclazide—Dyspepsia—Docetaxel—lung cancer	4.86e-05	0.000313	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—lung cancer	4.85e-05	0.000312	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—lung cancer	4.82e-05	0.000311	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—lung cancer	4.81e-05	0.00031	CcSEcCtD
Gliclazide—Hypersensitivity—Paclitaxel—lung cancer	4.8e-05	0.000309	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—lung cancer	4.77e-05	0.000308	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Docetaxel—lung cancer	4.76e-05	0.000307	CcSEcCtD
Gliclazide—Asthenia—Etoposide—lung cancer	4.76e-05	0.000307	CcSEcCtD
Gliclazide—Fatigue—Docetaxel—lung cancer	4.76e-05	0.000307	CcSEcCtD
Gliclazide—Nausea—Irinotecan—lung cancer	4.74e-05	0.000306	CcSEcCtD
Gliclazide—Pain—Docetaxel—lung cancer	4.72e-05	0.000304	CcSEcCtD
Gliclazide—Constipation—Docetaxel—lung cancer	4.72e-05	0.000304	CcSEcCtD
Gliclazide—Back pain—Methotrexate—lung cancer	4.71e-05	0.000304	CcSEcCtD
Gliclazide—Pruritus—Etoposide—lung cancer	4.7e-05	0.000303	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—lung cancer	4.67e-05	0.000301	CcSEcCtD
Gliclazide—Asthenia—Paclitaxel—lung cancer	4.67e-05	0.000301	CcSEcCtD
Gliclazide—Nausea—Gemcitabine—lung cancer	4.62e-05	0.000298	CcSEcCtD
Gliclazide—Vomiting—Cisplatin—lung cancer	4.61e-05	0.000297	CcSEcCtD
Gliclazide—Pruritus—Paclitaxel—lung cancer	4.61e-05	0.000297	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—lung cancer	4.58e-05	0.000295	CcSEcCtD
Gliclazide—Rash—Cisplatin—lung cancer	4.57e-05	0.000294	CcSEcCtD
Gliclazide—Dermatitis—Cisplatin—lung cancer	4.57e-05	0.000294	CcSEcCtD
Gliclazide—Feeling abnormal—Docetaxel—lung cancer	4.55e-05	0.000293	CcSEcCtD
Gliclazide—Diarrhoea—Etoposide—lung cancer	4.54e-05	0.000293	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—lung cancer	4.53e-05	0.000292	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—lung cancer	4.52e-05	0.000291	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—lung cancer	4.52e-05	0.000291	CcSEcCtD
Gliclazide—Gastrointestinal pain—Docetaxel—lung cancer	4.51e-05	0.000291	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—lung cancer	4.5e-05	0.00029	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—lung cancer	4.5e-05	0.00029	CcSEcCtD
Gliclazide—Diarrhoea—Paclitaxel—lung cancer	4.45e-05	0.000287	CcSEcCtD
Gliclazide—Malaise—Methotrexate—lung cancer	4.39e-05	0.000283	CcSEcCtD
Gliclazide—Dizziness—Etoposide—lung cancer	4.39e-05	0.000283	CcSEcCtD
Gliclazide—Abdominal pain—Docetaxel—lung cancer	4.36e-05	0.000281	CcSEcCtD
Gliclazide—Body temperature increased—Docetaxel—lung cancer	4.36e-05	0.000281	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—lung cancer	4.36e-05	0.000281	CcSEcCtD
Gliclazide—Chills—Doxorubicin—lung cancer	4.35e-05	0.00028	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—lung cancer	4.33e-05	0.000279	CcSEcCtD
Gliclazide—Dizziness—Paclitaxel—lung cancer	4.3e-05	0.000277	CcSEcCtD
Gliclazide—Nausea—Cisplatin—lung cancer	4.3e-05	0.000277	CcSEcCtD
Gliclazide—Cough—Methotrexate—lung cancer	4.25e-05	0.000274	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—lung cancer	4.25e-05	0.000274	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—lung cancer	4.22e-05	0.000272	CcSEcCtD
Gliclazide—Vomiting—Etoposide—lung cancer	4.22e-05	0.000272	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—lung cancer	4.22e-05	0.000272	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—lung cancer	4.22e-05	0.000272	CcSEcCtD
Gliclazide—Rash—Etoposide—lung cancer	4.19e-05	0.00027	CcSEcCtD
Gliclazide—Dermatitis—Etoposide—lung cancer	4.18e-05	0.00027	CcSEcCtD
Gliclazide—Headache—Etoposide—lung cancer	4.16e-05	0.000268	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—lung cancer	4.16e-05	0.000268	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—lung cancer	4.15e-05	0.000267	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—lung cancer	4.15e-05	0.000267	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—lung cancer	4.15e-05	0.000267	CcSEcCtD
Gliclazide—Tension—Doxorubicin—lung cancer	4.14e-05	0.000267	CcSEcCtD
Gliclazide—Vomiting—Paclitaxel—lung cancer	4.14e-05	0.000267	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	4.12e-05	0.000266	CcSEcCtD
Gliclazide—Rash—Paclitaxel—lung cancer	4.1e-05	0.000265	CcSEcCtD
Gliclazide—Dermatitis—Paclitaxel—lung cancer	4.1e-05	0.000264	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—lung cancer	4.1e-05	0.000264	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—lung cancer	4.1e-05	0.000264	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—lung cancer	4.08e-05	0.000263	CcSEcCtD
Gliclazide—Headache—Paclitaxel—lung cancer	4.08e-05	0.000263	CcSEcCtD
Gliclazide—Hypersensitivity—Docetaxel—lung cancer	4.07e-05	0.000262	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—lung cancer	4.01e-05	0.000258	CcSEcCtD
Gliclazide—Asthenia—Docetaxel—lung cancer	3.96e-05	0.000255	CcSEcCtD
Gliclazide—Infection—Methotrexate—lung cancer	3.95e-05	0.000255	CcSEcCtD
Gliclazide—Nausea—Etoposide—lung cancer	3.94e-05	0.000254	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—lung cancer	3.91e-05	0.000252	CcSEcCtD
Gliclazide—Pruritus—Docetaxel—lung cancer	3.9e-05	0.000252	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—lung cancer	3.9e-05	0.000251	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—lung cancer	3.9e-05	0.000251	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—lung cancer	3.89e-05	0.000251	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—lung cancer	3.88e-05	0.00025	CcSEcCtD
Gliclazide—Nausea—Paclitaxel—lung cancer	3.87e-05	0.000249	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—lung cancer	3.86e-05	0.000249	CcSEcCtD
Gliclazide—Hyperhidrosis—Methotrexate—lung cancer	3.84e-05	0.000248	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—lung cancer	3.81e-05	0.000245	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—lung cancer	3.78e-05	0.000243	CcSEcCtD
Gliclazide—Diarrhoea—Docetaxel—lung cancer	3.78e-05	0.000243	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—lung cancer	3.73e-05	0.00024	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—lung cancer	3.72e-05	0.000239	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—lung cancer	3.71e-05	0.000239	CcSEcCtD
Gliclazide—Cough—Doxorubicin—lung cancer	3.68e-05	0.000237	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—lung cancer	3.66e-05	0.000236	CcSEcCtD
Gliclazide—Dizziness—Docetaxel—lung cancer	3.65e-05	0.000235	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—lung cancer	3.64e-05	0.000235	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—lung cancer	3.62e-05	0.000234	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—lung cancer	3.6e-05	0.000232	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—lung cancer	3.59e-05	0.000232	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—lung cancer	3.59e-05	0.000232	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—lung cancer	3.59e-05	0.000232	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—lung cancer	3.58e-05	0.000231	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—lung cancer	3.57e-05	0.00023	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.57e-05	0.00023	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—lung cancer	3.55e-05	0.000229	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—lung cancer	3.55e-05	0.000228	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—lung cancer	3.54e-05	0.000228	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—lung cancer	3.51e-05	0.000226	CcSEcCtD
Gliclazide—Vomiting—Docetaxel—lung cancer	3.51e-05	0.000226	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—lung cancer	3.5e-05	0.000226	CcSEcCtD
Gliclazide—Rash—Docetaxel—lung cancer	3.48e-05	0.000224	CcSEcCtD
Gliclazide—Dermatitis—Docetaxel—lung cancer	3.48e-05	0.000224	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—lung cancer	3.47e-05	0.000224	CcSEcCtD
Gliclazide—Headache—Docetaxel—lung cancer	3.46e-05	0.000223	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—lung cancer	3.43e-05	0.000221	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—lung cancer	3.43e-05	0.000221	CcSEcCtD
Gliclazide—Infection—Doxorubicin—lung cancer	3.42e-05	0.00022	CcSEcCtD
Gliclazide—Pain—Methotrexate—lung cancer	3.4e-05	0.000219	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—lung cancer	3.38e-05	0.000218	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—lung cancer	3.37e-05	0.000217	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—lung cancer	3.36e-05	0.000217	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—lung cancer	3.34e-05	0.000216	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—lung cancer	3.33e-05	0.000215	CcSEcCtD
Gliclazide—Nausea—Docetaxel—lung cancer	3.28e-05	0.000211	CcSEcCtD
Gliclazide—Feeling abnormal—Methotrexate—lung cancer	3.28e-05	0.000211	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—lung cancer	3.25e-05	0.00021	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—lung cancer	3.22e-05	0.000207	CcSEcCtD
Gliclazide—Urticaria—Methotrexate—lung cancer	3.16e-05	0.000204	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—lung cancer	3.14e-05	0.000203	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—lung cancer	3.14e-05	0.000203	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—lung cancer	3.14e-05	0.000202	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—lung cancer	3.11e-05	0.000201	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—lung cancer	3.09e-05	0.000199	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—lung cancer	3.07e-05	0.000198	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—lung cancer	3.06e-05	0.000197	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—lung cancer	3.03e-05	0.000195	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Doxorubicin—lung cancer	2.97e-05	0.000192	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—lung cancer	2.97e-05	0.000191	CcSEcCtD
Gliclazide—Pain—Doxorubicin—lung cancer	2.94e-05	0.00019	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—lung cancer	2.94e-05	0.00019	CcSEcCtD
Gliclazide—Hypersensitivity—Methotrexate—lung cancer	2.93e-05	0.000189	CcSEcCtD
Gliclazide—Asthenia—Methotrexate—lung cancer	2.85e-05	0.000184	CcSEcCtD
Gliclazide—Feeling abnormal—Doxorubicin—lung cancer	2.84e-05	0.000183	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—lung cancer	2.82e-05	0.000181	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—lung cancer	2.81e-05	0.000181	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—lung cancer	2.74e-05	0.000176	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—lung cancer	2.72e-05	0.000175	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—lung cancer	2.72e-05	0.000175	CcSEcCtD
Gliclazide—Diarrhoea—Methotrexate—lung cancer	2.72e-05	0.000175	CcSEcCtD
Gliclazide—Dizziness—Methotrexate—lung cancer	2.63e-05	0.000169	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—lung cancer	2.54e-05	0.000164	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—lung cancer	2.53e-05	0.000163	CcSEcCtD
Gliclazide—Rash—Methotrexate—lung cancer	2.51e-05	0.000162	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—lung cancer	2.51e-05	0.000161	CcSEcCtD
Gliclazide—Headache—Methotrexate—lung cancer	2.49e-05	0.000161	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—lung cancer	2.47e-05	0.000159	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—lung cancer	2.44e-05	0.000157	CcSEcCtD
Gliclazide—Nausea—Methotrexate—lung cancer	2.36e-05	0.000152	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—lung cancer	2.36e-05	0.000152	CcSEcCtD
Gliclazide—Dizziness—Doxorubicin—lung cancer	2.28e-05	0.000147	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—lung cancer	2.19e-05	0.000141	CcSEcCtD
Gliclazide—Rash—Doxorubicin—lung cancer	2.17e-05	0.00014	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—lung cancer	2.17e-05	0.00014	CcSEcCtD
Gliclazide—Headache—Doxorubicin—lung cancer	2.16e-05	0.000139	CcSEcCtD
Gliclazide—Nausea—Doxorubicin—lung cancer	2.05e-05	0.000132	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—ERBB3—lung cancer	1.09e-05	9.33e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTA4—lung cancer	1.09e-05	9.32e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SDC4—lung cancer	1.07e-05	9.16e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTA3—lung cancer	1.07e-05	9.15e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RRM1—lung cancer	1.07e-05	9.15e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CREBBP—lung cancer	1.07e-05	9.14e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	1.07e-05	9.11e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—POMC—lung cancer	1.07e-05	9.1e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—lung cancer	1.07e-05	9.1e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTA2—lung cancer	1.06e-05	9.08e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MMP1—lung cancer	1.05e-05	8.98e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—lung cancer	1.05e-05	8.94e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CREBBP—lung cancer	1.04e-05	8.86e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTA1—lung cancer	1.03e-05	8.76e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGFR1—lung cancer	1.02e-05	8.68e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCC3—lung cancer	1.02e-05	8.67e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CD—lung cancer	1.02e-05	8.67e-05	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—lung cancer	1.01e-05	8.64e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK3—lung cancer	1.01e-05	8.6e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—B4GALT5—lung cancer	1.01e-05	8.6e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—APOA1—lung cancer	1.01e-05	8.59e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—lung cancer	1e-05	8.55e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HIF1A—lung cancer	1e-05	8.55e-05	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—lung cancer	9.93e-06	8.48e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CD—lung cancer	9.85e-06	8.4e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKR1C1—lung cancer	9.84e-06	8.39e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTA4—lung cancer	9.81e-06	8.37e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RRM1—lung cancer	9.78e-06	8.34e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA3—lung cancer	9.78e-06	8.34e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—lung cancer	9.72e-06	8.3e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOA1—lung cancer	9.67e-06	8.25e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	9.59e-06	8.18e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KDR—lung cancer	9.58e-06	8.17e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTA2—lung cancer	9.56e-06	8.16e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—UGT1A1—lung cancer	9.55e-06	8.15e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTA1—lung cancer	9.22e-06	7.87e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNG11—lung cancer	9.21e-06	7.86e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—B4GALT5—lung cancer	9.19e-06	7.84e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CG—lung cancer	9.19e-06	7.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOA1—lung cancer	9.16e-06	7.82e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCC3—lung cancer	9.12e-06	7.78e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EGF—lung cancer	9.08e-06	7.75e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA4—lung cancer	8.94e-06	7.63e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CB—lung cancer	8.85e-06	7.55e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKR1C1—lung cancer	8.83e-06	7.53e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KIT—lung cancer	8.83e-06	7.53e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CG—lung cancer	8.83e-06	7.53e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APC—lung cancer	8.83e-06	7.53e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—lung cancer	8.77e-06	7.48e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDOA—lung cancer	8.77e-06	7.48e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	8.74e-06	7.46e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGF—lung cancer	8.72e-06	7.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA2—lung cancer	8.71e-06	7.44e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—APOA1—lung cancer	8.71e-06	7.43e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CB—lung cancer	8.58e-06	7.32e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—UGT1A1—lung cancer	8.57e-06	7.31e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CREBBP—lung cancer	8.52e-06	7.27e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NCOA3—lung cancer	8.51e-06	7.26e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—lung cancer	8.51e-06	7.26e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA1—lung cancer	8.41e-06	7.17e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—POMC—lung cancer	8.4e-06	7.17e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	8.36e-06	7.14e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—lung cancer	8.33e-06	7.1e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCC3—lung cancer	8.31e-06	7.09e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—lung cancer	8.3e-06	7.08e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADCY1—lung cancer	8.28e-06	7.06e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCG2—lung cancer	8.28e-06	7.06e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNG11—lung cancer	8.27e-06	7.05e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—lung cancer	8.22e-06	7.02e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6R—lung cancer	8.19e-06	6.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CREBBP—lung cancer	8.18e-06	6.98e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HPGDS—lung cancer	8.12e-06	6.93e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO2—lung cancer	8.12e-06	6.93e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CD—lung cancer	8.08e-06	6.89e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPP2R1B—lung cancer	8.07e-06	6.88e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKR1C1—lung cancer	8.05e-06	6.87e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—POMC—lung cancer	7.96e-06	6.79e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTT1—lung cancer	7.88e-06	6.72e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDOA—lung cancer	7.87e-06	6.72e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—UGT1A1—lung cancer	7.82e-06	6.67e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAP2K1—lung cancer	7.81e-06	6.66e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2A6—lung cancer	7.78e-06	6.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GCLC—lung cancer	7.78e-06	6.64e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CD—lung cancer	7.76e-06	6.62e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	7.75e-06	6.62e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—lung cancer	7.65e-06	6.53e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOA3—lung cancer	7.64e-06	6.52e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNG11—lung cancer	7.54e-06	6.43e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	7.51e-06	6.41e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—lung cancer	7.5e-06	6.4e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCG2—lung cancer	7.43e-06	6.34e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADCY1—lung cancer	7.43e-06	6.34e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—lung cancer	7.42e-06	6.33e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO1—lung cancer	7.38e-06	6.3e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CREBBP—lung cancer	7.37e-06	6.29e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	7.35e-06	6.27e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—lung cancer	7.29e-06	6.22e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO2—lung cancer	7.29e-06	6.22e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HPGDS—lung cancer	7.29e-06	6.22e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPP2R1B—lung cancer	7.24e-06	6.18e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RAF1—lung cancer	7.21e-06	6.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDOA—lung cancer	7.18e-06	6.12e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—lung cancer	7.15e-06	6.1e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—lung cancer	7.07e-06	6.04e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTT1—lung cancer	7.07e-06	6.03e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CB—lung cancer	7.04e-06	6.01e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GCLC—lung cancer	6.99e-06	5.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2A6—lung cancer	6.99e-06	5.96e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOA3—lung cancer	6.97e-06	5.94e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	6.96e-06	5.94e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MDM2—lung cancer	6.95e-06	5.93e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RAF1—lung cancer	6.93e-06	5.91e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—lung cancer	6.85e-06	5.85e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	6.85e-06	5.84e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—lung cancer	6.8e-06	5.8e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCG2—lung cancer	6.78e-06	5.78e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADCY1—lung cancer	6.78e-06	5.78e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MTOR—lung cancer	6.76e-06	5.77e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CB—lung cancer	6.76e-06	5.77e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO2—lung cancer	6.65e-06	5.67e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HPGDS—lung cancer	6.65e-06	5.67e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO1—lung cancer	6.62e-06	5.65e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2E1—lung cancer	6.62e-06	5.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPP2R1B—lung cancer	6.6e-06	5.64e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	6.6e-06	5.63e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NQO1—lung cancer	6.55e-06	5.58e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	6.52e-06	5.56e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—lung cancer	6.52e-06	5.56e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—lung cancer	6.5e-06	5.55e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—lung cancer	6.47e-06	5.52e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTT1—lung cancer	6.45e-06	5.5e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	6.41e-06	5.47e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2A6—lung cancer	6.37e-06	5.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GCLC—lung cancer	6.37e-06	5.44e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	6.35e-06	5.42e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	6.35e-06	5.42e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—RAF1—lung cancer	6.24e-06	5.33e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—lung cancer	6.22e-06	5.31e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—lung cancer	6.21e-06	5.3e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—lung cancer	6.05e-06	5.17e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—lung cancer	6.04e-06	5.16e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO1—lung cancer	6.04e-06	5.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	6.02e-06	5.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2E1—lung cancer	5.94e-06	5.07e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	5.94e-06	5.07e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—STK11—lung cancer	5.9e-06	5.03e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—lung cancer	5.88e-06	5.02e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NQO1—lung cancer	5.88e-06	5.01e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—lung cancer	5.86e-06	5e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—lung cancer	5.84e-06	4.99e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—lung cancer	5.8e-06	4.95e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	5.75e-06	4.91e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	5.7e-06	4.86e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SRC—lung cancer	5.64e-06	4.81e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—lung cancer	5.57e-06	4.76e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—lung cancer	5.54e-06	4.73e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—lung cancer	5.49e-06	4.69e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—lung cancer	5.46e-06	4.66e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—lung cancer	5.43e-06	4.63e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SRC—lung cancer	5.42e-06	4.62e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2E1—lung cancer	5.42e-06	4.62e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—lung cancer	5.4e-06	4.6e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NQO1—lung cancer	5.36e-06	4.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CAT—lung cancer	5.31e-06	4.53e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—STK11—lung cancer	5.3e-06	4.52e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.28e-06	4.51e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	5.25e-06	4.48e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—lung cancer	5.23e-06	4.46e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—lung cancer	5.23e-06	4.46e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—lung cancer	5.21e-06	4.45e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	5.2e-06	4.44e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK3—lung cancer	5.2e-06	4.43e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—lung cancer	5.17e-06	4.41e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMS—lung cancer	5.07e-06	4.33e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—lung cancer	5.02e-06	4.28e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK3—lung cancer	4.99e-06	4.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	4.97e-06	4.24e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—lung cancer	4.9e-06	4.18e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—lung cancer	4.86e-06	4.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—STK11—lung cancer	4.83e-06	4.12e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CAT—lung cancer	4.77e-06	4.07e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1A1—lung cancer	4.76e-06	4.06e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—lung cancer	4.75e-06	4.05e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	4.74e-06	4.05e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ERCC2—lung cancer	4.72e-06	4.02e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—lung cancer	4.67e-06	3.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—lung cancer	4.64e-06	3.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMS—lung cancer	4.56e-06	3.89e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	4.53e-06	3.87e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—lung cancer	4.5e-06	3.84e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—lung cancer	4.49e-06	3.83e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—lung cancer	4.47e-06	3.81e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—lung cancer	4.41e-06	3.76e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CAT—lung cancer	4.35e-06	3.71e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	4.32e-06	3.69e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—lung cancer	4.29e-06	3.66e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—lung cancer	4.27e-06	3.65e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1A1—lung cancer	4.27e-06	3.64e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ERCC2—lung cancer	4.23e-06	3.61e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—lung cancer	4.23e-06	3.61e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMS—lung cancer	4.15e-06	3.54e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—lung cancer	4.15e-06	3.54e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—lung cancer	4.12e-06	3.52e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—lung cancer	4.11e-06	3.5e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOA1—lung cancer	4.08e-06	3.48e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—lung cancer	3.99e-06	3.4e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—lung cancer	3.97e-06	3.39e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.91e-06	3.33e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1A1—lung cancer	3.89e-06	3.32e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ERCC2—lung cancer	3.86e-06	3.29e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—lung cancer	3.81e-06	3.25e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—lung cancer	3.72e-06	3.18e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOA1—lung cancer	3.66e-06	3.13e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—lung cancer	3.65e-06	3.11e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—POMC—lung cancer	3.55e-06	3.03e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.51e-06	2.99e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—lung cancer	3.51e-06	2.99e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CREBBP—lung cancer	3.45e-06	2.95e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—lung cancer	3.37e-06	2.87e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—lung cancer	3.34e-06	2.85e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOA1—lung cancer	3.34e-06	2.85e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CD—lung cancer	3.27e-06	2.79e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.2e-06	2.73e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—POMC—lung cancer	3.18e-06	2.72e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CREBBP—lung cancer	3.1e-06	2.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—lung cancer	3.05e-06	2.6e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CD—lung cancer	2.94e-06	2.51e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—POMC—lung cancer	2.9e-06	2.48e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—lung cancer	2.9e-06	2.48e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CB—lung cancer	2.85e-06	2.44e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—lung cancer	2.83e-06	2.41e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CREBBP—lung cancer	2.83e-06	2.41e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CD—lung cancer	2.68e-06	2.29e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—lung cancer	2.65e-06	2.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CB—lung cancer	2.56e-06	2.19e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—lung cancer	2.54e-06	2.17e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—lung cancer	2.47e-06	2.1e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—lung cancer	2.35e-06	2.01e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CB—lung cancer	2.34e-06	1.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—lung cancer	2.31e-06	1.98e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—lung cancer	2.21e-06	1.89e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—lung cancer	2.11e-06	1.8e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—lung cancer	2.02e-06	1.72e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—lung cancer	1.93e-06	1.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—lung cancer	1.74e-06	1.48e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—lung cancer	1.56e-06	1.33e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—lung cancer	1.42e-06	1.22e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—lung cancer	1.42e-06	1.21e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—lung cancer	1.28e-06	1.09e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—lung cancer	1.16e-06	9.93e-06	CbGpPWpGaD
